Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 01, 2026
LyondellBasell (LYB) Q1 2026 Earnings Preview: Seeking Signs of Stabilization

LyondellBasell (LYB) Q1 2026 Earnings Preview: Seeking Signs of Stabilization

Key Takeaways

  • Analysts expect LYB to report first-quarter 2026 EPS of about $0.28-$0.31, a rebound from Q4 2025's loss of $0.26 per share.
  • Revenue consensus stands at approximately $7.37 billion, down slightly year-over-year due to softer chemical pricing.
  • Key focus on Olefins & Polyolefins (O&P) segment margins amid global oversupply and weak demand.
  • Company's cash improvement plan targets $1.3 billion by end-2026, supporting dividend stability.
  • Trailing earnings surprises average negative 63.8%, raising bar for positive reaction.
  • EBITDA (earnings before interest, taxes, depreciation, and amortization) expectations hinge on cost controls and volume stability.

Why LYB's Q1 2026 Earnings Matter

LyondellBasell Industries, one of the world's leading chemicals producers, is approaching its first-quarter 2026 earnings report at a critical juncture. Following a full-year 2025 net loss of $738 million—largely due to compressed margins and petrochemical oversupply—investors are looking for evidence of a turnaround. The company's diversified operations across O&P, Advanced Polymer Solutions, and refining give it potential exposure to recovering demand in packaging and durable goods. In my view, this report carries weight because it could highlight progress on the $1.3 billion cash improvement plan, shaping sentiment in an industry strained by overcapacity and economic headwinds. Positive outcomes here might reinforce LYB's appeal through its attractive dividend yield for income-focused investors.

Consensus Expectations for the Quarter

Wall Street forecasts point to Q1 2026 revenue of $7.37 billion for LyondellBasell, a slight dip from $7.677 billion in the prior-year quarter, mainly from lower average selling prices even as volumes hold steady. The consensus EPS estimate sits at $0.28, drawn from 15 analysts—a marked improvement over Q4 2025's $0.26 loss per share, though still trailing Q1 2025's $0.33 excluding identified items.

One area I'll be watching closely is EBITDA, projected in the $500-600 million range when adjusting historical trends for today's environment, along with segment breakdowns. Margins in the O&P segment will draw particular scrutiny given the ethylene and propylene glut. Updates on 2026 capex around $1.2 billion and ongoing cost savings will also matter. LYB has a recent track record of missing EPS targets, as seen in Q4 2025's -$0.26 actual versus $0.22 expected, yet the stock climbed afterward on hopes of recovery. Post-earnings moves have typically been volatile, often +5-10% on beats.

Market Sentiment Heading In

Sentiment toward LYB remains cautiously optimistic ahead of this release, with the Earnings Surprise Prediction (ESP) metric at +10.28% hinting at a possible beat. The shares demonstrated resilience after Q4's miss, supported by expectations around cost reductions. That said, risks linger from softer demand in Europe and China, as well as fluctuating energy costs. Options activity suggests an 8-10% swing post-earnings, consistent with past patterns. With peers in the chemicals sector under similar strain, much attention will fall on LYB's guidance.

Leveraging Tickeron’s AI Screener in My Analysis

In my research process, I often turn to Tickeron’s AI Screener, an AI-driven tool that lets me sift through stocks and ETFs using technical patterns, fundamentals, trends, volatility, and predictive signals. It scans thousands of names with filters for industry peers, market cap, indicators, price patterns, and metrics, surfacing ideas like breakout candidates or value plays far quicker than manual methods. For instance, I used it here to gauge how LYB stacks up against chemical sector peers—it's a straightforward way to spot relative opportunities and refine my outlook.

Looking Ahead: Key Factors to Track

Once the numbers are out, management's take on 2026 demand trends will take center stage. Petrochemical oversupply looks set to linger through mid-year, though potential supply disruptions might widen O&P spreads. Demand for oxyfuels, linked to refining operations, continues as a positive amid stable gasoline use.

Progress on the $1.3 billion cash generation target by year-end remains crucial, covering $1.2 billion in capex while sustaining the adjusted dividend. I'll also monitor margin gains in Intermediates & Derivatives from disciplined cost management.

On the bigger picture, advancements in U.S. Gulf Coast projects and sustainability efforts could provide tailwinds amid evolving regulations. Industry-wide chemical production growth of 1-3% supports the case, but global economic signals around packaging and construction will be telling. Strong execution on these fronts could set LYB up for better full-year results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LYB

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


LYB in upward trend: 10-day moving average broke above 50-day moving average on August 07, 2026

The 10-day moving average for LYB crossed bullishly above the 50-day moving average on August 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 10, 2026. You may want to consider a long position or call options on LYB as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

LYB moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LYB advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 197 cases where LYB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LYB moved out of overbought territory on August 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LYB broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.044) is normal, around the industry mean (7.001). P/E Ratio (98.766) is within average values for comparable stocks, (39.393). Projected Growth (PEG Ratio) (1.526) is also within normal values, averaging (2.393). LYB's Dividend Yield (0.061) is considerably higher than the industry average of (0.019). P/S Ratio (0.697) is also within normal values, averaging (70.976).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LYB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.

Notable companies

The most notable companies in this group are DuPont de Nemours (NYSE:DD), Chemours Company (The) (NYSE:CC).

Industry description

The specialty chemicals sector includes companies that produce chemicals and industrial gases, which are of relatively high-value, often made to customer specifications. Examples of specialty chemicals are electronic chemicals, industrial gases, coatings, adhesives and sealants, industrial and institutional cleaning chemicals. The products are often valued on the basis of their purposes/performances rather than for their composition. Linde Plc, Ecolab Inc., Air Products and Chemicals, Inc., and Dow, Inc. are some of the largest companies making specialty chemicals.

Market Cap

The average market capitalization across the Chemicals: Specialty Industry is 12.06B. The market cap for tickers in the group ranges from 47 to 224.76B. LIN holds the highest valuation in this group at 224.76B. The lowest valued company is GTBT at 47.

High and low price notable news

The average weekly price growth across all stocks in the Chemicals: Specialty Industry was -1%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 6%. CITR experienced the highest price growth at 21%, while LWLG experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Chemicals: Specialty Industry was 25%. For the same stocks of the Industry, the average monthly volume growth was -14% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 58
Price Growth Rating: 51
SMR Rating: 77
Profit Risk Rating: 81
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
LYB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of petrochemicals

Industry ChemicalsSpecialty

Profile
Details
Industry
Chemicals Specialty
Address
One Vine Street
Phone
+44 2072202600
Employees
20000
Web
https://www.lyondellbasell.com
Interact to see
Advertisement
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.